Clinical Trials
32 trialsA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Amgen
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
Amgen
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
National Cancer Institute (NCI)
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
M.D. Anderson Cancer Center
TEADCO
Orion Corporation, Orion Pharma
Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).
Amgen
MERIT-lung
Fundación GECP
CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer
Roswell Park Cancer Institute
Krascendo 1
Hoffmann-La Roche
Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors
Deciphera Pharmaceuticals, LLC
Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer
City of Hope Medical Center
A Study of Sotorasib in People With Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)
Memorial Sloan Kettering Cancer Center
RAMP203
Verastem, Inc.
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
Revolution Medicines, Inc.
Ladarixin With Sotorasib in Advanced NSCLC
NYU Langone Health
Tarlox and Sotorasib in Patients With KRAS G12C Mutations
Medical University of South Carolina
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
CodeBreaK201
Amgen
CODEBREAK-IGR
Gustave Roussy, Cancer Campus, Grand Paris
VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer
Vitrac Therapeutics, LLC
JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
Allist Pharmaceuticals, Inc.
Argonaut
Navire Pharma Inc., a BridgeBio company
AMBER
ETOP IBCSG Partners Foundation
ROSIE
Radboud University Medical Center
Ladarixin With Sotorasib in Advanced NSCLC - Phase II
NYU Langone Health
K-SAB
Karolinska University Hospital
SOLUCOM
Vestre Viken Hospital Trust
A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis
Criterium, Inc.
HERKULES-2
Erasca, Inc.
Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC
Fox Chase Cancer Center
breakthrough
Yonsei University